Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/17055| Title: | Personalized chemosensitivity assays for mesothelioma- is it worth the effort? | Austin Authors: | John, Thomas ;Chia, Puey Ling | Affiliation: | Medical Oncology, Olivia Newton-John Cancer Research Institute Medical Oncology, University of Melbourne, Olivia Newton-John Cancer Research Institute. |
Issue Date: | 19-Jan-2018 | Date: | 2018 | Publication information: | Clinical Cancer Research 2018; online first: 19 January | Abstract: | Cell-lines formed from an individual's tumor can be used to predict response to specific therapies and determine genomic predictors. For mesothelioma, where chemotherapy remains the backbone of current therapeutic paradigms, such assays could be used to treat patients with the most effective agents specific to their "chemical profile". | URI: | https://ahro.austin.org.au/austinjspui/handle/1/17055 | DOI: | 10.1158/1078-0432.CCR-17-3493 | Journal: | Clinical Cancer Research | PubMed URL: | 29351918 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/29351918 | ISSN: | 1078-0432 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.